Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Expenses (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Operating Expenses for 9 consecutive years, with $53.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 32.64% to $53.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $173.2 million, a 17.47% increase, with the full-year FY2025 number at $173.2 million, up 17.47% from a year prior.
  • Operating Expenses was $53.6 million for Q4 2025 at Akebia Therapeutics, up from $44.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $88.8 million in Q1 2022 to a low of $35.3 million in Q2 2024.
  • A 5-year average of $55.1 million and a median of $46.8 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 48.89% in 2023, then skyrocketed 32.64% in 2025.
  • Akebia Therapeutics' Operating Expenses stood at $75.4 million in 2021, then dropped by 13.25% to $65.4 million in 2022, then plummeted by 44.71% to $36.2 million in 2023, then increased by 11.84% to $40.4 million in 2024, then surged by 32.64% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Operating Expenses are $53.6 million (Q4 2025), $44.9 million (Q3 2025), and $38.5 million (Q2 2025).